Sagimet Biosciences Inc. (SGMT) has a negative trailing P/E of -3.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -28.69%.
Criteria proven by this page:
Overall SharesGrow Score: 56/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -24.8 | 0.00 | -2.82 | 0.00 | - |
| 2020 | -31.1 | 1.53 | -2.60 | 0.00 | - |
| 2021 | -14.5 | -0.13 | -2.23 | 0.00 | - |
| 2022 | -11.6 | -0.46 | -1.89 | 0.00 | - |
| 2023 | -3.5 | -0.33 | 1.08 | 49.31 | - |
| 2024 | -3.1 | 0.59 | 0.91 | 0.00 | - |
| 2025 | -3.8 | -0.42 | 1.72 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.64 | $0.00 | $-14.26M | - |
| 2020 | $-0.51 | $0.00 | $-11.37M | - |
| 2021 | $-1.10 | $0.00 | $-24.44M | - |
| 2022 | $-1.38 | $0.00 | $-30.5M | - |
| 2023 | $-2.66 | $2M | $-27.88M | -1393.8% |
| 2024 | $-1.45 | $0.00 | $-45.57M | - |
| 2025 | $-1.58 | $0.00 | $-51.04M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.68 | $-2.05 – $-1.14 | $111.11K | $111.11K – $111.11K | 7 |
| 2027 | $-1.91 | $-2.93 – $-0.87 | $4.28M | $4.28M – $4.28M | 7 |
| 2028 | $-2.09 | $-3.44 – $-0.86 | $8.89M | $8.89M – $8.89M | 8 |
| 2029 | $-2.41 | $-2.41 – $-2.41 | $29.14M | $29.14M – $29.14M | 6 |
| 2030 | $-1.22 | $-1.22 – $-1.22 | $117.82M | $117.82M – $117.82M | 6 |
